The estimated Net Worth of Mark L Baum is at least 90 百万$ dollars as of 22 March 2024. Mr. Baum owns over 9,000 units of Harrow Health stock worth over 88,429,409$ and over the last 11 years he sold HROW stock worth over 219,135$. In addition, he makes 1,377,010$ as Chief Executive Officer、 Director at Harrow Health.
Mark has made over 16 trades of the Harrow Health stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of HROW stock worth 104,310$ on 22 March 2024.
The largest trade he's ever made was exercising 850,000 units of Harrow Health stock on 25 April 2021 worth over 35,164,500$. On average, Mark trades about 85,147 units every 95 days since 2013. As of 22 March 2024 he still owns at least 2,137,525 units of Harrow Health stock.
You can see the complete history of Mr. Baum stock trades at the bottom of the page.
Mark L. Baum J.D. serves as Chief Executive Officer, Director of the Company. In 2011, Mr. Baum led the restructuring and reorganization of Harrow and since that time has directed the creation, development and growth of the Company’s unique business model. Mr. Baum was appointed as a director of the Company in December 2011, served as the Chairman of the Board of Directors from December 2011 to April 2012, and was appointed as Chief Executive Officer in April 2012. Prior to Mr. Baum’s involvement with the Company, from 2001 to 2011, he was the founder and managing director of TBLF, LLC, a consulting firm and fund manager, where he managed a series of three funds and acted as a principal investor in financing publicly traded companies or bridge-to-public equity transactions. Before his fund management experience, Mr. Baum founded and served as the president of YesRx, and practiced as a U.S. securities lawyer focused on public company reporting requirements and finance-related matters. Mr. Baum is also a founder and board member of Eton Pharmaceuticals, Inc., Surface Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., and our subsidiaries Mayfield Pharmaceuticals, Inc., and Radley Pharmaceuticals, Inc. From November 2012 until December 2017, Mr. Baum served on the board of directors for Ideal Power, Inc., where he was also chair of its audit committee. Mr. Baum brings years of public company executive and board experience, including knowledge of securities laws, reporting requirements and public company finance-related issues. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a graduate of California Western School of Law.
As the Chief Executive Officer、 Director of Harrow Health, the total compensation of Mark Baum at Harrow Health is 1,377,010$. There are no executives at Harrow Health getting paid more.
Mark Baum is 47, he's been the Chief Executive Officer、 Director of Harrow Health since 2012. There are 9 older and 2 younger executives at Harrow Health. The oldest executive at Harrow Health, Inc. is Dr. Robert J. Kammer D.D.S., 72, who is the Special Advisor.
Mark's mailing address filed with the SEC is C/O HARROW, INC., 102 WOODMONT BLVD, SUITE 610, NASHVILLE, TN, 37205.
Over the last 6 years, insiders at Harrow Health have traded over 1,363,111$ worth of Harrow Health stock and bought 1,487,560 units worth 12,882,479$ . The most active insiders traders include Management Inc. Opaleye、Mark L Baum、Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days with the average trade being worth of 3,323,914$. The most recent stock trade was executed by Management Inc. Opaleye on 25 April 2024, trading 20,000 units of HROW stock currently worth 199,400$.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Harrow Health executives and other stock owners filed with the SEC include: